Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Estefanía Moreno is active.

Publication


Featured researches published by Estefanía Moreno.


British Journal of Pharmacology | 2009

Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors

Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I. Canela; Rob Leurs; Sergi Ferré; Carme Lluis; Rafael Franco

Background and purpose:  Functional interactions between the G protein‐coupled dopamine D1 and histamine H3 receptors have been described in the brain. In the present study we investigated the existence of D1–H3 receptor heteromers and their biochemical characteristics.


Journal of Biological Chemistry | 2012

Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain

Lucía Callén; Estefanía Moreno; Pedro Barroso-Chinea; David Moreno-Delgado; Antoni Cortés; Josefa Mallol; Vicent Casadó; José L. Lanciego; Rafael Franco; Carmen Lluis; Enric I. Canela; Peter J. McCormick

Background: Although CB1, the most abundant neuronal receptors, and CB2 receptors are co-expressed in neurons, the CB1-CB2 relationship is unknown. Results: CB1 and CB2 receptors form heteromers in neuronal cells and in the brain. Conclusion: Activation of either receptor leads to negative modulation of the partner receptor via heteromers. Significance: These heteromers may explain previous conflicting results and serve as therapeutic targets. Exploring the role of cannabinoid CB2 receptors in the brain, we present evidence of CB2 receptor molecular and functional interaction with cannabinoid CB1 receptors. Using biophysical and biochemical approaches, we discovered that CB2 receptors can form heteromers with CB1 receptors in transfected neuronal cells and in rat brain pineal gland, nucleus accumbens, and globus pallidus. Within CB1-CB2 receptor heteromers expressed in a neuronal cell model, agonist co-activation of CB1 and CB2 receptors resulted in a negative cross-talk in Akt phosphorylation and neurite outgrowth. Moreover, one specific characteristic of CB1-CB2 receptor heteromers consists of both the ability of CB1 receptor antagonists to block the effect of CB2 receptor agonists and, conversely, the ability of CB2 receptor antagonists to block the effect of CB1 receptor agonists, showing a bidirectional cross-antagonism phenomenon. Taken together, these data illuminate the mechanism by which CB2 receptors can negatively modulate CB1 receptor function.


Proceedings of the National Academy of Sciences of the United States of America | 2010

Direct involvement of σ-1 receptors in the dopamine D1 receptor-mediated effects of cocaine

Gemma Navarro; Estefanía Moreno; Marisol S. Aymerich; Daniel Marcellino; Peter J. McCormick; Josefa Mallol; Antoni Cortés; Vicent Casadó; Enric I. Canela; Jordi Ortiz; Kjell Fuxe; Carmen Lluis; Sergi Ferré; Rafael Franco

It is well known that cocaine blocks the dopamine transporter. This mechanism should lead to a general increase in dopaminergic neurotransmission, and yet dopamine D1 receptors (D1Rs) play a more significant role in the behavioral effects of cocaine than the other dopamine receptor subtypes. Cocaine also binds to σ-1 receptors, the physiological role of which is largely unknown. In the present study, D1R and σ1R were found to heteromerize in transfected cells, where cocaine robustly potentiated D1R-mediated adenylyl cyclase activation, induced MAPK activation per se and counteracted MAPK activation induced by D1R stimulation in a dopamine transporter-independent and σ1R-dependent manner. Some of these effects were also demonstrated in murine striatal slices and were absent in σ1R KO mice, providing evidence for the existence of σ1R-D1R heteromers in the brain. Therefore, these results provide a molecular explanation for which D1R plays a more significant role in the behavioral effects of cocaine, through σ1R-D1R heteromerization, and provide a unique perspective toward understanding the molecular basis of cocaine addiction.


PLOS Biology | 2012

Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland

Sergio Gonzalez; David Moreno-Delgado; Estefanía Moreno; Kamil Pérez-Capote; Rafael Franco; Josefa Mallol; Antoni Cortés; Vicent Casadó; Carme Lluis; Jordi Ortiz; Sergi Ferré; Enric I. Canela; Peter J. McCormick

Dopamine and adrenergic receptor complexes form under a circadian-regulated cycle and directly modulate melatonin synthesis and release from the pineal gland.


Journal of Biological Chemistry | 2012

Cannabinoid receptors CB1 and CB2 form functional heteromers in the brain

Lucía Callén; Estefanía Moreno; Pedro Barroso-Chinea; David Moreno-Delgado; Antoni Cortés; Josefa Mallol; Vicent Casadó; José L. Lanciego; Rafael Franco; Carmen Lluis; Enric I. Canela; Peter J. McCormick

Background: Although CB1, the most abundant neuronal receptors, and CB2 receptors are co-expressed in neurons, the CB1-CB2 relationship is unknown. Results: CB1 and CB2 receptors form heteromers in neuronal cells and in the brain. Conclusion: Activation of either receptor leads to negative modulation of the partner receptor via heteromers. Significance: These heteromers may explain previous conflicting results and serve as therapeutic targets. Exploring the role of cannabinoid CB2 receptors in the brain, we present evidence of CB2 receptor molecular and functional interaction with cannabinoid CB1 receptors. Using biophysical and biochemical approaches, we discovered that CB2 receptors can form heteromers with CB1 receptors in transfected neuronal cells and in rat brain pineal gland, nucleus accumbens, and globus pallidus. Within CB1-CB2 receptor heteromers expressed in a neuronal cell model, agonist co-activation of CB1 and CB2 receptors resulted in a negative cross-talk in Akt phosphorylation and neurite outgrowth. Moreover, one specific characteristic of CB1-CB2 receptor heteromers consists of both the ability of CB1 receptor antagonists to block the effect of CB2 receptor agonists and, conversely, the ability of CB2 receptor antagonists to block the effect of CB1 receptor agonists, showing a bidirectional cross-antagonism phenomenon. Taken together, these data illuminate the mechanism by which CB2 receptors can negatively modulate CB1 receptor function.


Journal of Biological Chemistry | 2010

Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers.

Gemma Navarro; Sergi Ferré; Arnau Cordomí; Estefanía Moreno; Josefa Mallol; Vicent Casadó; Antoni Cortés; Hanne Hoffmann; Jordi Ortiz; Enric I. Canela; Carme Lluis; Leonardo Pardo; Rafael Franco; Amina S. Woods

G protein-coupled receptor (GPCR) heteromers are macromolecular complexes with unique functional properties different from those of its individual protomers. Little is known about what determines the quaternary structure of GPCR heteromers resulting in their unique functional properties. In this study, using resonance energy transfer techniques in experiments with mutated receptors, we provide for the first time clear evidence for a key role of intracellular domains in the determination of the quaternary structure of GPCR heteromers between adenosine A2A, cannabinoid CB1, and dopamine D2 receptors. In these interactions, arginine-rich epitopes form salt bridges with phosphorylated serine or threonine residues from CK1/2 consensus sites. Each receptor (A2A, CB1, and D2) was found to include two evolutionarily conserved intracellular domains to establish selective electrostatic interactions with intracellular domains of the other two receptors, indicating that these particular electrostatic interactions constitute a general mechanism for receptor heteromerization. Mutation experiments indicated that the interactions of the intracellular domains of the CB1 receptor with A2A and D2 receptors are fundamental for the correct formation of the quaternary structure needed for the function (MAPK signaling) of the A2A-CB1-D2 receptor heteromers. Analysis of MAPK signaling in striatal slices of CB1 receptor KO mice and wild-type littermates supported the existence of A1-CB1-D2 receptor heteromer in the brain. These findings allowed us to propose the first molecular model of the quaternary structure of a receptor heteromultimer.


Journal of Biological Chemistry | 2011

Dopamine D1-histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway

Estefanía Moreno; Hanne Hoffmann; Marta González-Sepúlveda; Gemma Navarro; Vicent Casadó; Antoni Cortés; Josefa Mallol; Michel Vignes; Peter J. McCormick; Enric I. Canela; Carme Lluis; Rosario Moratalla; Sergi Ferré; Jordi Ortiz; Rafael Franco

Previously, using artificial cell systems, we identified receptor heteromers between the dopamine D1 or D2 receptors and the histamine H3 receptor. In addition, we demonstrated two biochemical characteristics of the dopamine D1 receptor-histamine H3 receptor heteromer. We have now extended this work to show the dopamine D1 receptor-histamine H3 receptor heteromer exists in the brain and serves to provide a novel link between the MAPK pathway and the GABAergic neurons in the direct striatal efferent pathway. Using the biochemical characteristics identified previously, we found that the ability of H3 receptor activation to stimulate p44 and p42 extracellular signal-regulated MAPK (ERK 1/2) phosphorylation was only observed in striatal slices of mice expressing D1 receptors but not in D1 receptor-deficient mice. On the other hand, the ability of both D1 and H3 receptor antagonists to block MAPK activation induced by either D1 or H3 receptor agonists was also found in striatal slices. Taken together, these data indicate the occurrence of D1-H3 receptor complexes in the striatum and, more importantly, that H3 receptor agonist-induced ERK 1/2 phosphorylation in striatal slices is mediated by D1-H3 receptor heteromers. Moreover, H3 receptor-mediated phospho-ERK 1/2 labeling co-distributed with D1 receptor-containing but not with D2 receptor-containing striatal neurons. These results indicate that D1-H3 receptor heteromers work as processors integrating dopamine- and histamine-related signals involved in controlling the function of striatal neurons of the direct striatal pathway.


Neuropharmacology | 2013

Mechanisms of cannabidiol neuroprotection in hypoxic–ischemic newborn pigs: Role of 5HT1A and CB2 receptors

M. Ruth Pazos; Nagat Mohammed; Hector Lafuente; Martín Santos; Eva Martínez-Pinilla; Estefanía Moreno; Elsa M. Valdizán; Julián Romero; Angel Pazos; Rafael Franco; Cecilia J. Hillard; Francisco J. Alvarez; José Martínez-Orgado

The mechanisms underlying the neuroprotective effects of cannabidiol (CBD) were studied in vivo using a hypoxic-ischemic (HI) brain injury model in newborn pigs. One- to two-day-old piglets were exposed to HI for 30 min by interrupting carotid blood flow and reducing the fraction of inspired oxygen to 10%. Thirty minutes after HI, the piglets were treated with vehicle (HV) or 1 mg/kg CBD, alone (HC) or in combination with 1 mg/kg of a CB₂ receptor antagonist (AM630) or a serotonin 5HT(1A) receptor antagonist (WAY100635). HI decreased the number of viable neurons and affected the amplitude-integrated EEG background activity as well as different prognostic proton-magnetic-resonance-spectroscopy (H(±)-MRS)-detectable biomarkers (lactate/N-acetylaspartate and N-acetylaspartate/choline ratios). HI brain damage was also associated with increases in excitotoxicity (increased glutamate/N-acetylaspartate ratio), oxidative stress (decreased glutathione/creatine ratio and increased protein carbonylation) and inflammation (increased brain IL-1 levels). CBD administration after HI prevented all these alterations, although this CBD-mediated neuroprotection was reversed by co-administration of either WAY100635 or AM630, suggesting the involvement of CB₂ and 5HT(1A) receptors. The involvement of CB₂ receptors was not dependent on a CBD-mediated increase in endocannabinoids. Finally, bioluminescence resonance energy transfer studies indicated that CB₂ and 5HT(1A) receptors may form heteromers in living HEK-293T cells. In conclusion, our findings demonstrate that CBD exerts robust neuroprotective effects in vivo in HI piglets, modulating excitotoxicity, oxidative stress and inflammation, and that both CB₂ and 5HT(1A) receptors are implicated in these effects.


PLOS ONE | 2013

Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers

Gemma Navarro; Estefanía Moreno; Jordi Bonaventura; Marc Brugarolas; Daniel Farré; David Aguinaga; Josefa Mallol; Antoni Cortés; Vicent Casadó; Carmen Lluis; Sergi Ferré; Rafael Franco; Enric I. Canela; Peter J. McCormick

Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons containing the D1-like family of dopamine receptors and inputs of aversion coming from neurons containing the D2-like family of dopamine receptors. Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two pathways such that D1 reward seeking pathway dominates. Here, we provide an explanation at the cellular and biochemical level how cocaine may achieve this. Exploring the effect of cocaine on dopamine D2 receptors function, we present evidence of σ1 receptor molecular and functional interaction with dopamine D2 receptors. Using biophysical, biochemical, and cell biology approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with σ1 receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers. We demonstrate that the σ1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to σ1 -D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum. In contrast, in striatum from σ1 knockout animals these complexes are not found and this inhibition is not seen. Taken together, these data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor containing neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor containing neurons in the brain.


Proceedings of the National Academy of Sciences of the United States of America | 2015

Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer

Jordi Bonaventura; Gemma Navarro; Verònica Casadó-Anguera; Karima Azdad; William Rea; Estefanía Moreno; Marc Brugarolas; Josefa Mallol; Enric I. Canela; Carme Lluis; Antoni Cortés; Nora D. Volkow; Serge N. Schiffmann; Sergi Ferré; Vicent Casadó

Significance G protein-coupled receptors (GPCRs) constitute the largest plasma membrane protein family involved in cell signaling. GPCR homodimers are predominant species, and GPCR heteromers likely are constituted by heteromers of homodimers. The adenosine A2A receptor (A2AR)-dopamine D2 receptor (D2R) heteromer is a target for the nonselective adenosine receptor antagonist caffeine. This study uncovers allosteric modulations of A2AR antagonists that mimic those of A2AR agonists, challenging the traditional view of antagonists as inactive ligands. These allosteric modulations disappear when agonist and antagonist are coadministered, however. A model is proposed that considers A2AR-D2R heteromers as heterotetramers, constituted by A2AR and D2R homodimers. The model predicted that high concentrations of A2AR antagonists would behave as A2AR agonists and decrease D2R function in the brain. Adenosine A2A receptor (A2AR)-dopamine D2 receptor (D2R) heteromers are key modulators of striatal neuronal function. It has been suggested that the psychostimulant effects of caffeine depend on its ability to block an allosteric modulation within the A2AR-D2R heteromer, by which adenosine decreases the affinity and intrinsic efficacy of dopamine at the D2R. We describe novel unsuspected allosteric mechanisms within the heteromer by which not only A2AR agonists, but also A2AR antagonists, decrease the affinity and intrinsic efficacy of D2R agonists and the affinity of D2R antagonists. Strikingly, these allosteric modulations disappear on agonist and antagonist coadministration. This can be explained by a model that considers A2AR-D2R heteromers as heterotetramers, constituted by A2AR and D2R homodimers, as demonstrated by experiments with bioluminescence resonance energy transfer and bimolecular fluorescence and bioluminescence complementation. As predicted by the model, high concentrations of A2AR antagonists behaved as A2AR agonists and decreased D2R function in the brain.

Collaboration


Dive into the Estefanía Moreno's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carme Lluis

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Sergi Ferré

National Institute on Drug Abuse

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carmen Lluis

University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge